GLENMARK2,403.10

Glenmark Pharmaceuticals Ltd.

· Pharma & Health
₹ CrorePeersDRREDDYLUPINALKEMBIOCONMANKINDLAURUSLABSFORTISAUROPHARMAMcap ₹67,815 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation630.8486.0573.5
+ Finance Costs517.4207.1208.7
+ Interest Income-17.3-43.9-41.3
+ Dividend Income-0.00.00.0
+ Fair Value (Gains) / Losses-745.00.0-0.0
+ Share-based Payments5.0-9.226.8
+ Unrealised FX (Gain) / Loss-342.6-69.1-380.4
+ Other Non-cash Items900.1373.12,266.1
+ Other — Cash Effects are Investing / Financing-7.1-2.4-0.0
+ Other Reconciling Items555.637.417.0
Changes in Working Capital
+ Inventories-513.9-450.8-752.3
+ Trade Receivables — Current969.5-1,420.3-1,750.5
+ Other Current Assets-518.2156.2-648.9
+ Trade Payables — Current-751.8-813.82,704.6
+ Provisions — Current62.83.120.1
Cash from Operating Activities
Profit Before Tax (per I/S)36.51,399.21,984.72,532.6
+ Total Adjustments (incl. Working Capital)745.6-1,546.72,243.3
Cash from Operations (pre-tax)782.0-147.54,228.0
+ Income Taxes Paid1,047.5680.1783.0
Cash from Operating Activities-265.4-827.63,445.0
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)898.4749.61,357.7
+ Disp of Investment Property2.12.42.3
+ Acq of Other Long-term Assets16.50.00.0
+ Sale of Investments (Equity / Debt)7.1735.7-0.2
+ Disp of Subsidiaries / Businesses (net)5,449.60.00.0
+ Dividends Received — Investing0.00.00.0
+ Interest Received — Investing17.242.141.5
+ Other Inflows / (Outflows) — Investing-191.9-28.630.8
Cash from Investing Activities4,369.12.1-1,283.2
Cash from Financing Activities
+ Proceeds from Issue of Shares1.20.00.8
+ Buyback / Redemption of Own Shares0.030.10.0
+ Proceeds from Borrowings481.11,341.2-1,715.7
+ Repayment of Borrowings3,649.5140.7530.0
+ Payment of Lease Liabilities104.4122.2135.4
+ Interest Paid516.8190.8187.4
+ Dividends Paid117.870.4141.0
Cash from Financing Activities-3,906.1787.0-2,708.8
Net Changes in Cash (pre-FX)197.6-38.5-547.0
+ Effect of FX Rate Changes on Cash17.755.946.0
Net Changes in Cash215.217.4-501.0
Closing Cash1,658.31,675.7
Reference Items
EBITDA1,195.32,351.44,572.44,796.7
EBITDA Margin %10.1217.6526.9227.04
Free Cash Flow (CFO − Capex)-1,163.8-1,577.22,087.32,087.3
Free Cash Flow to Equity-564.3-294.3
Free Cash Flow per Basic Share-41.24-55.8973.9773.97
Price to Free Cash Flow32.49
Cash Flow to Net Income0.19-0.792.53
Cash Paid for Taxes1,047.5680.1783.0
Cash Paid for Interest516.8190.8187.4
As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.